Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taxane · 1 trial · 1 indication
CR was defined for target lesions (TLs) as the disappearance of all lesions, and for nontarget lesions (NTLs) as the disappearance of all nontarget nonmeasurable lesions. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs. 95% confidence interval for one-sample binomial using Pearson-Clopper method.
| Arm | Type | Description |
|---|---|---|
| Trastuzumab Monotherapy | ACTIVE_COMPARATOR | Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death. |
| Trastuzumab, Taxane | EXPERIMENTAL | Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator. |
| Name | Type | Description |
|---|---|---|
| Trastuzumab | DRUG | 4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death. |
| Taxane (docetaxel or paclitaxel) | DRUG | Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab. |
Inclusion Criteria: * at least 10 months of Herceptin treatment for HER2-positive early breast cancer; * metastatic breast cancer \>=12 months after discontinuation of Herceptin; * measurable disease. Exclusion Criteria: * previous chemotherapy for metastatic breast cancer; * brain metastases; * ...
Top 20 of 92 competitors
Taxane is a small molecule oncology drug being studied for the treatment of breast cancer. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being evaluated in patients with metastatic breast cancer, as part of a completed clinical trial.
Taxane is being developed by Roche Holding AG, a biopharmaceutical company traded under the ticker RHHBY. The drug is a small molecule in the oncology therapeutic area, currently in Phase 2 clinical development for breast cancer.
Taxane is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial for the drug has been completed, with no active trials currently ongoing.
Taxane has one completed clinical trial, NCT00475670, titled 'A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer.' This Phase 2 trial enrolled 44 female patients aged 18 years and older with breast cancer, and was conducted across multiple countries including Australia, Canada, and Germany.
Taxane is not the same as Herceptin. The clinical trial NCT00475670 studied Herceptin (trastuzumab) in combination with Taxane in women with metastatic breast cancer. Taxane is a separate investigational drug being developed by Roche Holding AG for breast cancer.